Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: Results from a randomized phase II study

Palliative Medicine

Volumn 24, Issue 3, 2010, Pages 286-293

  LennernÄs, Bo ^a   Frank Lissbrant, Ingela ^a   LennernÄs, Hans ^b   KÄlkner, Karl Mikael ^c   Derrick, Rob ^d   Howell, Julian ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Cancer; Fentanyl; Opioid; Pain; Sublingual

Indexed keywords

FENTANYL; PLACEBO;

ADULT; AGED; ANALGESIA; ANEMIA; ARTICLE; BREAKTHROUGH PAIN; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEATH; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FACE EDEMA; FEMALE; FEVER; GENERAL CONDITION DETERIORATION; HEMATURIA; HUMAN; LOWER ABDOMINAL PAIN; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SINGLE DRUG DOSE; STOMACH PAIN; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE RETENTION; VOMITING;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CROSS-OVER STUDIES; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PAIN; PAIN MEASUREMENT; PLACEBOS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950617998     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269216309356138     Document Type: Article

References (17)

1. Svendsen KB, Andersen S., Arnason S., et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005 ; 9: 195-206. (Pubitemid 40311842)
2. Davies AN Cancer-related breakthrough pain. Br J Hosp Med (Lond) 2006 ; 67: 414-416.
3. Caraceni A., Portenoy RK An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999 ; 82: 263-274.
4. Goudas LC, Bloch R., Gialeli-Goudas M., et al. The epidemiology of cancer pain. Cancer Invest 2005 ; 23: 182-190. (Pubitemid 40463916)
5. Portenoy RK, Hagen NA Breakthrough pain: definition, prevalence and characteristics. Pain 1990 ; 41: 273-281.
6. Portenoy RK, Hagen NA Breakthrough pain: definition and management. Oncology (Williston Park) 1989 ; 3: 25-29.
7. Rhiner M., Palos G., Termini M. Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate. Clin J Oncol Nurs 2004 ; 8: 507-512.
8. Roy SD, Flynn GL Solubility and related physicochemical properties of narcotic analgesics. Pharm Res 1988 ; 5: 580-586.
9. Coluzzi PH, Schwartzberg L., Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001 ; 91: 123-130.
10. Labroo RB, Paine MF, Thummel KE, Kharasch ED Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997 ; 25: 1072-1080. (Pubitemid 27396495)
11. Ozdemir V., Kalow W., Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000 ; 10: 373-388. (Pubitemid 30433571)
12. Zhang H., Zhang J., Streisand JB Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002 ; 41: 661-680.
13. Shojaei AH Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998 ; 1: 15-30.
14. Bredenberg S., Duberg M., Lennernas B., et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 2003 ; 20: 327-334. (Pubitemid 37338538)
15. Lennernas B., Hedner T., Holmberg M., et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005 ; 59: 249-253. (Pubitemid 40208864)
16. PSI Professional Standards Working Party. Guidelines for standard operating procedures for good statistical practice in clinical research. Statisticians in the pharmaceutical industry, version 6, 1 June 2000. http://www.psiweb.org/docs/gsop.pdf (last accessed July 2009 ).
17. Farrar JT, Berlin JA, Strom BL Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003 ; 25: 406-411.